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Abstract 
We have previously reported I170T mutation of transforming growth factor- ß receptor II (TßR-II) 
in human oral squamous cell carcinoma samples. To analyze the functional consequences of I170T 
TßR-II mutation, we performed co-immunoprecipitation of TßR-II with TßR-I and determined 
intracellular signaling activities of TßR-II. As a result, either wild type or I170T mutant TßR-II was co-
precipitated with TßR-I, regardless of TGF-ß and both wild-type and I170T mutant TßR-II exhibited 
similar levels of transcriptional activities upon treatment of TGF-ß1. Moreover, I170T TßR-II localized 
at the cell membrane similar to wild-type TßR-II. Our data showed that I170T mutation of TßR-II does 
not affect the receptor oligomerization, membrane localization, and downstream signaling upon 
binding of TGF-ß1. Taken together, these results indicate that I170T mutation of TßR-II does not 
change structural or physiological characteristics of TßR-II, raising the possibility that I170T might be 
a new SNP of TßR-II. 
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1. Introduction 
 
Transforming growth factor-ß (TGF-ß is a family of diverse growth factors that regulate 
proliferation, differentiation, motility, and apoptosis in various cell types [1]. The various actions of 
TGF-ß can be switched by substitute pathways. TGF-ß signaling exhibits tumor suppressive activities 
in the early stages of tumorigenesis, however, at the later stage, it exerts oncogenic activities [2]. TGF-
ßinitiates cell signaling via dimerization of type I and type II receptors [3]. Type II receptor (TßR-II), 
which binds to TGF-ßrecruits type I receptor (TßR-I), and the stimulated TßR-I phosphorylates smad2 
and smad3, which form complex with smad4. Then the complex translocates into the nucleus and 
controls transcription of TGF-ß target genes [4]. 
Mutations of TßR-II have been found in many human cancers mostly resulting in the loss of tumor 
suppressor function of TßR-II [5]. Previously, we have reported novel mutations of TßR-II from 
normal, dysplastic, cancerous region and metastatic lymph nodes (if available) from 18 patients with 
oral squamous cell carcinoma [6], among which E221V/N238I mutation enhanced TGF-ß signaling by 
acting as a tumor promoter [7].  
A single-nucleotide polymorphism (SNP) is a DNA sequence variation occurring when a 
single nucleotide in the genome differs between members of a biological species. SNP can make minor 
changes or no alteration in properties of human compared with severe mutations [8]. Nonetheless, 
some SNPs from TßR-II have been reported to be associated with several diseases including sudden 
cardiac arrest in patients with coronary artery disease [9] and vulnerability to intracerebral hemorrhage 
[10].  
Codon 170 is located in the transmembrane domain of TßR-II and I170T mutation was identified in 
normal and dysplastic region of two patients, respectively. This study aimed at investigating the 
functional consequence of I170T mutation of TßR-II and suggests that I170T might be a new SNP of 
TßR-II. 
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2. Materials and Methods  
 
2.1. Reagents 
 
TGF-ß1, human recombinant protein was acquired from Calbiochem (San Diego, CA). cDNAs for 
human TßR-I and TßR-II were obtained from Origene (Rockville, MD). 3TP-lux, TGF-ß luciferase 
promoter-repoter, was purchased from Addgene and pRL-TK (Renilla reniformis luciferase under 
thymidine kinase promoter) was purchased from Promega. Restriction enzymes, BamHI, ClaI, XbaI, 
XhoI and SacII, were acquired from New England Biolabs (Beverly, MA). 
 
2.2. Cell culture and transfection 
  
DR26 mutant cells that lack functional TßR-II (generously provided by Dr. J. Massague (Memorial 
Sloan-Kettering Cancer Center, New York, NY)), COS-7 and HeLa cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM; Biowhittaker, USA) with 10% fetal bovine serum (FBS) at 37℃ 
in the presence of 5% CO2. Cells were transiently transfected using LipofectaminTM 2000 (Invitrogen) 
according to the manufacturer’s protocol. 
 
2.3. Luciferase assay 
 
Luciferase assay was performed as described [7]. The data were normalized for transfection 
efficiency using Renilla luciferase activity. 
 
2.4. Cloning and Mutagenesis 
  
A TßR-II mutant with a threonine residue instead of Ile170 was constructed by site-directed 
mutagenesis using PCR. Primers used for site-directed mutagenesis are 
CAAGTGACAGGCACCAGCCTCCTGC (sense) and GCAGGAGGCTGGTGCCTGTCACTTG 
(antisense). Firstly, two sets of PCR were done using primers, F-BamHI with antisense and sense with 
R-XbaI. Then, PCR products of two sets of first PCR were used as templates for the second round of 
PCR using primers, F-BamHI and R-XbaI. The PCR product with mutation was digested with both 
corresponding restriction enzymes and then ligated to the vector to generate I170T TßR-II. All of the 
PCR products were sequenced. 
 
2.5. Co-immunoprecipitation and immunobloting 
 
COS-7 cells were transfected with TßR-II and TßR-I construct and treated with TGF-ß at 24 hr 
after tranfection. COS-7 cells were washed with binding buffer (phosphate-buffered saline (PBS) 
containing 0.9 mM CaCl2, 0.49 mM MgCl2, 1 mg/ml bovine serum albumin (BSA)) and treated with 2 
ng/ml of TGF-ß1 in binding buffer for 3 hr at 4℃. For cross-linking of TGF-ß and TGF-ß receptors, 
cells were washed with binding buffer without BSA and followed by treatment with 0.5 mM of BS3 in 
binding buffer without BSA for 30 min at 4℃. Cells were washed with cold PBS and lysed in Cell 
Lysis Buffer (Cell Signaling Technology, Beverly, MA). Antibodies against TßR-I or anti-Flag (or 
TßR-II) were added to cell extracts and incubated overnight at 4℃. Then protein A-agarose (Sigma) 
was added and incubated for 1 hr and the immune complexes were isolated. Protein complexes were 
then analyzed by using primary antibodies (TßR-I (V-22), TßR-II (C-16) or anti-Flag M2).  
 
2.6. Localization of TGF-ß RII 
 
COS-7 cells were cultured on glass chamber slides and wild type RII-EYFP or I170T mutant RII-
EYFP were transfected as described above. Cells were fixed with 4% paraformaldehyde for 10 min and 
the fluorescence signals were detected, captured and analyzed by LSM 510 laser scanning confocal 
microscope and image examiner (Carl Zeiss MicroImaging Inc., Thornwood, NY). 
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3. Results 
 
3.1. Identification of a novel missense mutation in oral squamous cell carcinoma samples  
 
A novel mutation of TßR-II with a single amino acid change from ATC(Ile) to ACC(Thr) in codon 
170 was detected in normal and dysplastic region of two oral squamous cell carcinoma samples. Amino 
acid 170 resides in the transmembrane domain of TßR-II. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Identification of mutation at 170 amino acid of TßR-II from patients of oral squamous 
cell carcinoma. The PCR products were sequenced using MegaBACE 1000. In the analyzed result, 
Five amino acids before and after mutant amino acid are included. Single amino acid was changed 
from ATC(Iie) to ACC(Thr) in codon 170 of exon 4. (a) codon 170 of wild type TßR-II. (b) codon 170 
of mutant TßR-II. 
 
3.2. Interaction of mutant TßR-II with TßR-I  
 
We tested whether the I170T mutant TßR-II can interact with TßR-I. Wild-type and mutant TßR-II 
were transiently transfected into COS-7 cells and the interaction with endogenous TßR-I was analyzed 
in the presence or absence of TGF-ß1. Immunoprecipitation was performed against TßR-I or flag tag of 
exogenous TßR-II. Fig. 2 showed that both wild-type and I170T mutant TßR-II can interact with TßR-I 
with similar efficiency. Moreover, these interactions were not affected by the presence of TGF-ß1. 
These results indicate that I170T mutation of TßR-II does not affect the interaction between TßR-I and 
TßR-II. 
 
 
Figure 2. Co-immunoprecipitation of TßR-I and TßR-II. A. TßRI and wild type or mutant TßR-II 
constructs with flag tag were transfected into COS-7 cells. Immune complexes were precipitated by 
adding antibodies against TßR-I to the cell extracts and analyzed. B. Immunoprecipitation was 
performed as in (A) except that anti-flag M2 antibody was used. 
 
3.3 Intracellular signaling activities of mutant TßR-II  
 
To compare the intracellular signaling activities of wild-type and mutant TßR-II, we carried out 
luciferase assay. p3TP-lux promoter-reporter construct, pRL-TK and wild type or mutant TßR-II were 
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transiently co-transfected into DR mutant cells. TGF-ß1 was treated to final concentration of 1 ng/ml. 
Signaling activities of both wild-type and mutant TßR-II were increased by TGF-ß1 treatment. But, 
there was no significant difference between wild type and mutant TßR-II (Fig. 3), further suggesting 
that I170T mutation of TßR-II does affect TGF-ßsignaling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Transcriptional activities of wild-type and I170T TßR-II. Luciferase assay was performed 
to analyze the transcriptional activities induced by TßR-II constructs. DR cells were co-transfected 
with p3TP-lux promoter-reporter construct, pRL-TK and wild type TßR-II or I170T TßR-II, and then 
stimulated with TGF-ß1. Values of transfection efficiency were normalized using Renilla luciferase. 
 
3.4. Localization of I170T TßR-II in the cell membrane  
 
Since I170T mutation resides in transmembrane domain of TßR-II, we then tested whether the 
membrane localization of TßR-II was affected by this mutation. TßR-II constructs with C-terrminal 
EYFP was generated and transfected into COS-7 cells. Both wild-type and mutant TßR-II were shown 
to localize at the cell membrane (Fig. 4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Localization of wild-type and I170T TßR-II.  Wild-type or I170T TßR-II-EYFP 
constructs were transfected into COS-7 cells to determine the localization of TßR-II. 0.2 ng/ml of TGF-
ß was treated for 1 hr to identify the changes of TßR-II localization. 
 
4. Discussion 
 
A large number of missense mutations were identified in protein kinase domain of TßR-II while a 
few identified in extracellular domain of TßR-II. Most mutations in TßR-II were involved in the 
impairment of the TGF-ßsignaling as growth inhibitor in epithelial cells, resulting in tumor 
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progression [11] [12]. Garrigue-Antar L et al. reported two controversial missense mutations of TßR-II. 
One mutation was unable to phosphorylate TßR-I, however, the other one was constitutively stimulated 
[13]. In addition, mutation of functional binding sites in TßR-II impairs the intracellular signaling 
activity and ligand binding [14]. We have previously reported a novel gain-of-function mutation of 
TßR-II which harbors double mutation at E221V/N238I [7]. This mutant receptor enhanced the TGF-ß 
signaling presumably due to delayed TßRII internalization. In the current study we sought to analyze 
the I170T mutation of TßR-II identified in OSCC samples. I170T mutation was identified in two 
OSCC patient samples including normal region and dysplastic region, respectively. Since amino acid 
170 resides in transmembrane domain of TßR-II and no mutation in the transmembrane domain has 
been reported, we compared the activities of wild-type and I170T mutant TßR-II. 
Intracellular signaling activities of wild-type and mutant TßR-II were similar and were also 
similarly augmented by TGF-ß1 treatment. Several studies proposed that the cell surface level of the 
TßR-II determines the intensity of TGF-ß signaling . Therefore, we examined the membrane 
localization of TßR-II. I170T mutant TßR-II appeared to localize at the cell membrane with similar 
intensity to the wild-type receptor, further supporting that I170T mutation does not affect the structure 
and TGF-ß signaling activities of TßR-II. These results suggest that I170T might be a new SNP which 
does not affect TßR-II activities. 
 
5. Conclusion   
 
Taken together, I170T mutation of TßR-II in transmembrane domain might be a new SNP of TßR-II, 
which does not alter structural and functional properties of TßR-II. 
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